AAPL 190.97 -1.17 (-0.61%)MSFT 117.13 -0.45 (-0.38%)FB 164.38 -0.35 (-0.21%)ZNGA 5.3 -0.13 (-2.31%)NVDA 177.47 +0.21 (+0.12%)WBA 62.43 -0.13 (-0.21%)GOOG 1205.9 -0.04 (-0.00%)PIH 5.45 -0.16 (-2.85%)
AAPL 190.97 -1.17 (-0.61%)MSFT 117.13 -0.45 (-0.38%)FB 164.38 -0.35 (-0.21%)ZNGA 5.3 -0.13 (-2.31%)NVDA 177.47 +0.21 (+0.12%)WBA 62.43 -0.13 (-0.21%)GOOG 1205.9 -0.04 (-0.00%)PIH 5.45 -0.16 (-2.85%)

Cash Flow APHB Quote AmpliPhi Bi

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -1 -19 -13
Depreciation 0 0 0
DeferredIncomeT 0 -1 -1
StockBasedCompe 0 2 1
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 0 0
OtherWorkingCap 0 0 -1
OtherNonCashIte -10 -4 -1
NetCashProvided -10 -11 -9
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 0
DebtIssued 0 0 0
DebtRepayment 0 0 -1
CommonStockIssu 0 8 9
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 13 0 0
NetCashProvided 13 7 9
NetChangeInCash 3 -4 -1
CashAtBeginning 7 9 6
CashAtEndOfPeri 9 6 5
AmpliPhi Biosciences Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AmpliPhi Biosciences Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.